Start: 09 Nov 2021, 13:15
End: 09 Nov 2021, 14:00

Chair: Dr Michael Braun, The Christie NHS Foundation Trust, UK
Speaker: Dr Janet Graham, The Beatson West of Scotland Cancer Centre, UK
Speaker: Dr Naureen Starling, The Royal Marsden NHS Foundation Trust, UK

Together, the panel will:

•Discuss the importance of BRAFV600E testing for the mCRC patient population and the timing of testing to ensure first treatment decisions can be made to maximise treatment options at all lines of the patient pathway.

•Highlight the poor prognosis of the BRAFV600E mCRC patient population.1
1.Kopetz S et al.N Engl J Med 2019;381:1632-1643

•Share current guidance for both BRAF testing and BRAFTOVI (encorafenib) use within its licensed indication.

•Highlight key data from the BEACON CRC trial and implications for real-world clinical practice.

•Share clinical experience of prescribing encorafenib and cetuximab within its licensed indication in BRAFV600E mutant mCRC through case studies.

•Generate a panel discussion and pre-recorded Q and A session.

Pierre Fabre logo

Session labels: